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Abstract 
Background 
DNA methylation of promoter-associated CpG islands of certain genes may play a role in the 
development of colorectal cancer. The MYOD-1 gene which is a muscle differentiation gene 
has been showed to be significantly methylated in colorectal cancer which, is an age related 
event. However the role of this gene in the colonic mucosa is not understood and whether 
methylation occurs in subjects without colon cancer. In this study, we have determined the 
frequency of methylation of the MYOD-1 gene in normal colonic mucosa and investigated to 
see if this is associated with established colorectal cancer risk factors primarily ageing. 
Results 
We analysed colonic mucosal biopsies in 218 normal individuals and demonstrated that in 
most individuals promoter hypermethylation was not quantified for MYOD-1. However, 
promoter hypermethylation increased significantly with age (p < 0.001 using regression 
analysis) and this was gender independent. We also showed that gene promoter methylation 
increased positively with an increase in waist to hip (WHR) ratio – the latter is also a known 
risk factor for colon cancer development. 
Conclusions 
Our study suggests that promoter gene hypermethylation of the MYOD-1 gene increases 
significantly with age in normal individuals and thus may offer potential as a putative 
biomarker for colorectal cancer. 
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Background 
Genetic alterations leading to mutations in tumour suppressor genes and oncogenes only 
characterise 10% of colorectal cancers. Various genetic and epigenetic modifications that 
lead to heritable changes in gene function but unrelated to changes in DNA sequence are 
understood to be mechanisms that cause development of cancer [1-4]. One of the most 
studied changes that are linked to neoplasia is aberrant DNA methylation. Gene specific 
hypermethylation can result in reduced gene expression/silencing with consequent detriment 
to the colonocyte, particularly if key genes such as tumour suppressor genes are involved 
[5,6]. It has also been suggested that detecting hypermethylation of these genes in blood or 
stool samples may prove to be a non invasive method of detecting those at risk of colon 
cancer [7]. 
DNA hypermethylation has been investigated extensively in colorectal cancer and other pre-
malignant diseases and many genes specifically affected by CpG methylation have been 
identified. The MYOD-1 gene is one such gene which is located on chromosome 11, is 
mainly expressed in skeletal muscle. Several studies have demonstrated hypermethylation of 
this gene in tumour tissue and to a lesser extent in the normal adjacent colon [8,9]. The 
function of this gene is of particular interest as although it is a specific muscle regulator, it is 
capable of inducing myogenesis in other cell types and may interact with other stem cell 
lineages [10,11]. However, its role in the morphologically normal colon is poorly studied as 
all the studies have been carried out to look at its epigenetic marking in colorectal adenomas 
& cancer. Ahuja et al. [8] have shown significant hypermethylation of MYOD-1 in colon 
cancer tissue compared to adjacent normal mucosa and this also increases with in age. 
Unfortunately there is a paucity of robust studies looking at the role of these genes in the 
colon and the state of methylation in healthy individuals as this would help appreciate the 
epigenetic changes with certain risk factors associated with colon cancer. This study proposes 
to look at the gene specific methylation patterns of MYOD-1 gene within the colon in normal 
individuals, in an attempt to understand its relationship with known risk factors of colon 
cancer including age, lifestyle and anthropometric measures (waist to hip ratio (WHR)). 
Results 
No outliers were identified for methylation of the promoter regions MYOD-1. Frequency 
histograms for the methylation data are shown in Figure 1. The observed distribution 
observed for MYOD-1 was 60% of individuals with no detectable levels of methylation, 30% 
with methylation levels of 10 – 25% and a small proportion (< 5%) with higher levels of 
methylation; between 50 – 75%. 
Figure 1 Percentage of methylation of MYOD-1 
Age and gene specific methylation pattern for MYOD −1 
Logistic regression analysis demonstrated that methylation of MYOD-1 was highly 
significantly associated with age (p < 0.001) with a greater proportion of individuals over the 
age of 40 having detectable methylation. No association with sex was noted after adjusting 
for age. As it is well recognised that the incidence of colorectal cancers doubles after the age 
of 40, further analysis was performed in these two groups– see Table 1. A three year follow 
up of these patients revealed that none of these patients developed colon cancer. 
Table 1 Summary of percentage methylation for MYOD-1 and subgroup analysis of 
those under and over 40 years of age 
 MYOD-1 % (sd) 
Male  8.60 (14) 
Female 6.10 (9.1) 
Total 7.31 (11) 
Age Group  
< 40 years 3.59 (11) 
≥ 40 years 8.48 (11) 
Anthropometric measures and lifestyle factors and methylation of MYOD −1 
WHR but not BMI was significantly (p = 0.024) positively associated with detectable MYOD-
1 gene methylation after adjusting for age. There were no associations between smoking 
habit, or alcohol consumption and detectable MYOD-1 methylation. 
Discussion 
This study is the largest to date which has endeavoured to characterise patterns of 
methylation of MYOD-1 gene in individuals with normal colorectal mucosa. . This gene has 
been shown previously to demonstrate an increase in methylation with age and in colorectal 
tumour tissue. The majority of individuals in this study had either no or low detectable 
methylation of MYOD-1 which implies that in normal individuals this gene is not silenced 
through hypermethylation and may have a distinct role in disease whether it is age related, 
inflammatory or neoplastic. To date no studies have looked at the role of MYOD-1 in colonic 
mucosa and whether it plays a role as a tumour suppressor. 
We have demonstrated that hypermethylation on MYOD-1 was significantly higher in 
subjects aged over 40. For every decade increase in age of this study population, there was a 
10% increase in percentage detectable methylation [12]. This is consistent with the study 
performed by Ahuja et al. [8] and Hiranuma et al. [9] which showed a significant age related 
methylation of MYOD-1 in normal colonic mucosa and neoplastic mucosa. Age accounted for 
up to 11% and WHR 13% of the proportion of variation in MYOD-1 methylation. WHR is an 
important index of marker for colorectal cancers and methylation of certain genes (hMLH1) 
have been observed more frequently in those who are overweight [13]. 
Colorectal cancers are amongst the few cancers subjected to the intensive DNA methylation 
profiling, where changes in methylation in tumour samples were classified as age related as 
well as the cancer specific [14]. This methylation profile of multiple genes including MYOD-
1 is called “CpG island methylation phenotype (CIMP)”, and it is suggested that an unknown 
genetic mechanism in colorectal cancer may contribute to the clustering profile of the DNA 
methylation of the multiple genes together [15]. One such study by Xiao-Li Xu [16] that 
looked at the methylation profile of 31 genes demonstrated that altered promoter CpG island 
methylation patterns of 17 genes (including MYOD-1) were common with distinguished 
hallmarks specific to the early phase of colon carcinogenesis. However there was no 
significant correlation detected between the changes in the methylation patterns with any 
given clinical-pathological features apart from ageing. This adds support to findings in 
several studies which demonstrated that methylation of this gene increases with age and is 
present in colorectal cancers. 
Our study reinforces the significance of methylation of certain genes that may lead to 
development of colorectal cancer. The role of MYOD-1 gene in the colon is not well 
understood. One study showed that it played a role in the intestine smooth muscle 
development in ducks as the gene was highly expressed in the small intestines during the 
embryonic phase. Gene expression dropped rapidly following embryogenesis but it is unclear 
if it played an active role in adult development [17]. The significance of promoter 
methylation of MYOD-1 as its function in normal colonic mucosa remains unclear. 
As this was primarily an observational study there were a few limitations with it. We did not 
expect MYOD-1 to be methylated in normal colonic tissue and this was a novel finding. 
Further studies conducted to examine the role of MYOD-1 methylation as a biomarker should 
be case controlled against a colorectal cancer population in order to draw sensitivities and 
predictive values. Future studies should also compare MYOD-1 with MLH-1 methylation to 
see how this correlates together with increasing risk of colorectal cancer. Taken together our 
findings lends support to the hypothesis that promoter methylation of MYOD-1 may be an 
early biomarker of CRC risk since we have shown positive association with ageing and 
increasing WHR, both of which are established risk factors for developing colon cancer [18]. 
Future studies should also include measurement of mRNA levels of MYOD-1 gene in normal 
colonic mucosa and specifically in colorectal cancers and correlation in mutated crypts. 
Conclusions 
We have for the first time demonstrated that promoter methylation of MYOD-1 gene is a 
potential biomarker for detecting risk of colorectal cancer and warrants further research to 
establish its role into clinical practice. 
Methods 
218 subjects (105 male, 113 female) were analysed as part of the BORICC study. All patients 
had normal endoscopic examinations – main symptom was overt rectal bleeding. They did not 
have any significant past medical history and their investigations were all normal. 
Histological findings of colonic mucosal biopsies were also reported as normal. The baseline 
characteristics of these subjects are defined in Table 2. Gene specific DNA methylation was 
quantified in DNA from colonic mucosal biopsies and was expressed as percentage 
methylation of MYOD-1. Additional measurements made include demographic details, 
smoking habit and anthropometric measures. 
Table 2 Summary of subject characteristics 
Characteristics 
(n = 218) 
 
Male 105 
Female 113 
Age <40 52 
Age >40  166 
Mean age (sd) 50 (13) 
Mean BMI (sd) 28 (6) 
Mean WHR 0.89 (0.09) 
Smokers 51 (23%) 
Assessment of DNA methylation 
Tissue mucosal samples weighed 3–5 mg and DNA was extracted as per the manufacturer’s 
protocol (QIAGEN, QIAmp® DNA mini kit). Proteinase K was added and samples were 
heated to 56oC overnight to ensure complete tissue lysis. Additional RNAase treatment was 
carried out to ensure RNA free DNA samples. Only samples which had an A260/280 
wavelength (Eppendorf® Biophotometer) ratio greater than 1.7 were utilised. 
DNA methylation at specific gene loci was quantified by the COBRA technique (Combined 
Bisulphite Modified Restriction Enzyme Analysis) described by Xiong et al. [19] in which 
DNA was treated with sodium bisulphite followed by PCR and restriction enzyme digestion. 
The genomic region of interest was PCR amplified using primer sets designed specifically to 
contain no CpG dinucleotides. This step ensured that all templates were amplified equally 
regardless of the methylation status of the original genomic sequence. Following digestion 
with restriction enzymes separation of the digestion products using agarose gel 
electrophoresis, the DNA bands were visualised using Sybr green staining and the bands 
representing methylated and unmethylated sequences quantified using UVI software (UVI 
Tech Ltd.). In this study, the loci of interest were in the promoter regions of the MYOD-1 
gene. 
Statistical analysis 
SPSS v15 was used for all data analysis.. For the purpose of statistical analysis, MYOD-1 
methylation was categorised binomially i.e. those samples with no detectable methylation 
(zero value) and those with detectable methylation (given a value of 1). Binary logistic 
regression was employed to determine its relationship with dependant variables (age, 
anthropometric measures etc.). Statistical significance was defined as p ≤ 0.05. 
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